

AUTHOR INDEX

- Abbott, R. R. See Bhagchandani, L.
 Abbruzzese, J. L. See Moor, D. F., Jr.; Pazdur, R.
 Adenis, A.
 —Carlier, D.; Darloy, F.; Pion, J. M.; Bonnetterre, J.; Demaille, A.; French Northern Oncology Group: Cytarabine and cisplatin as salvage therapy in patients with metastatic colorectal cancer who failed 5-fluorouracil + folinic acid regimen, 158
 Agarwala, S. S.
 —Bahnsen, R. R.; Wilson, J. W.; Szumowski, J.; Ernstoff, M. S.: Evaluation of the combination of vinblastine and quinidine in patients with metastatic renal cell carcinoma: A Phase I study, 211
 Ahmann, F. See Marshall, M. E.
 Aitini, E. See Di Leo, A.
 Ajani, J. A. See Pazdur, R.
 Alessandrini, L. See Arcangeli, G.
 Amato, S. See Vallejo, C. T.
 Ambrogio, C. See Arcangeli, G.
 Amir, G. See Ron, I. G.
 Anderson, L. See Krywicki, R.
 Anderson, P. J. See Smith, D. E.
 Andresen, S. W. See Kalaycioglu, M. E.
 Andrulis, I. L. See Warner, E.
 Angelini, F. See Arcangeli, G.
 Anscher, M. S.
 —Prostate bed massage as a means to determine the source of a rising prostate specific antigen after radical prostatectomy, 481
 Antoine, E. C.
 —Rixe, O.; Vuillemin, E.; Benhammouda, A.; Borel, C.; Ghironzi, G. C.; Mularoni, E.; Franks, C.; Auclerc, G.; Soubrane, C.; Banzet, P.; Weil, M.; Khayat, D.: A Phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma
 Antunovic, V. See Jeremic, B.
 Aqual, S. See Girdler, N. M.
 Arase, Y. See Ikeda, K.
 Arcangeli, G. See Arcangeli, G.
 —Angelini, F.; Arcangeli, G.; Tersigni, R.; D'Aprile, M.; Micheli, A.; Veltri, E.; Ambrogio, C.; Alessandrini, L.; Giovannazzo, G.; D'Angelo, L.: A pilot study of concomitant protracted venous infusion 5-fluorouracil and hyperfractionated radiotherapy in rectal tumors, 369
 Asbury, R.
 —Blessing, J. A.; Smith, D. M.; Carson, L. F.: Aminothiadiazole in the treatment of advanced leiomyosarcoma of the uterine corpus, 397
 Ascari, E. See Federico, M.
 Ata, E. See Malik, I. A.
 Athanassiou, A. See Pectasides, D.
 Atlan, D.
 —Chevallier, B.; Sheng, R. G.: Tamoxifen for the treatment of metastatic inflammatory breast carcinoma, 74
 Atree, S. V.
 —Crilley, P. A.; Conroy, J. F.; Micaily, B.; Brodsky, J. T.: Cancer of the esophagus following allogeneic bone marrow transplantation for acute leukemia, 343
 Auclerc, G. See Antoine, E. C.
 Ausili-Cefaro, G.
 —Marmioli, L.; Nardone, L.; Salvi, G.: Prolonged continuous infusion of carboplatin and concomitant radiotherapy in advanced head and neck cancer: A Phase I study, 273
 Avanzini, P. See Federico, M.
 Aydiner, A.
 —Bugra, Z.; Topuz, E.; Meric, M.: Acute myocardial infarction in man treated with epirubicin for non-Hodgkin lymphoma, 444
 Baert, L. See Vandenbroucke, F.
 Bahnsen, R. R. See Agarwala, S. S.
 Baillet, F. See Maulard, C.
 Bajetta, E. See Di Leo, A.
 Baker, T. R. See Hempling, R. E.
 Bander, J. J. See LoRusso, P. M.
 Banzet, P. See Antoine, E. C.
 Barbieri, M. R. See Vallejo, C. T.
 Belanger, R. See Stewart, D. J.
 Benhammouda, A. See Antoine, E. C.
 Benjamin, R. S. See Kleiner, E. S.; Patel, S. R.; Stewart, D. J.
 Benson, A. B., III See Clark, J. L.
 Berruti, A. See Dogliotti, L.
 Berry, M. See Francois, A.
 Bertelli, G. See Pronzato, P.
 Bertetto, O. See Dogliotti, L.
 Bhagchandani, L.
 —Sanadi, R. E.; Sattar, S.; Abbott, R. R.: Basal cell carcinoma presenting as a finger mass: A case report, 176
 Bian, A. R. See Di Leo, A.
 Bielamowicz, S. See Smith, D. E.
 Biganzoli, L. See Di Leo, A.
 Billiet, I. See Vandenbroucke, F.
 Birkhofer, M. See Olver, I.
 Birnbaum, E. See Myerson, R. J.
 Bishop, J. See Olver, I.
 Bitran, J. D.
 —Green, M.; Perry, M.; Hollis, D. R.; Herndon, J. E., II: A Phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer, 67
 Black, P. See Seegenschmiedt, M. H.
 Blessing, J. A. See Asbury, R.; Look, K. Y.; Malfetano, J. H.; Manetta, A.
 Blumenreich, M. See Joseph, G.
 Blumenstein, B. See Marshall, M. E.
 Bochicchio, A. M. See Di Leo, A.
 Boegel, F. See Nemunaitis, J.
 Bolwell, B. J. See Kalaycioglu, M. E.
 Bonnel, C. See Caudry, M.
 Bonnetterre, J. See Adenis, A.
 Bookman, M. See Broun, E. R.
 Borel, C. See Antoine, E. C.
 Bowen, K. See Krywicki, R.
 Brady, L. W. See Seegenschmiedt, M. H.
 Braly, P. D. See McClay, E. F.
 Bready, B. See Moor, D. F., Jr.; Pazdur, R.
 Broder, L. E.
 —Sridhar, K. S.; Selawry, O. S.; Charyulu, K. N.; Rao, R. K.; Saldana, K. J.; Donnelly, E. J.; Raub, W. A., Jr.: A randomized clinical trial in bronchogenic small-cell carcinoma evaluating alternating maintenance therapy of vincristine, Adriamycin, procarbazine, and etoposide (VAPE) with cyclophosphamide, CCNU, and methotrexate (CCM) versus CCM maintenance alone in complete responders following VAPE induction and late intensification (Er-ratum), 462

- Brodsky, J. T. See Atree, S. V.
 Broun, E. R.
 —Iseminger, K. A.; Bookman, M.: A Phase II trial of edatrexate in previously treated ovarian cancer, 164
 Brunel, P. See Maulard, C.
 Bruno, S.
 —Puerto, V. L.; Mickiewicz, E.; Hegg, R.; Teixeira, L. C.; Gaitan, L.; Martinez, L.; Fernandez, O.; Otero, J.; Kesselring, G.; Noguera, C.; Delgado, G.; Gaubert, P.; Delgado, F. M.; Solidoro, A.: Phase II trial of weekly IV vinorelbine as a single agent in first-line advanced breast cancer chemotherapy: The Latin-American experience, 392
 Bugra, Z. See Aydinler, A.
 Burgess, M. A. See Patel, S. R.
 Butt, A. See Malik, I. A.
 Buzzdar, A. U. See Ibrahim, N. K.
 Buzzoni, E. See Di Leo, A.
 Cabanillas, F. F. See Herrada, J.
 Campbell, K. See Stuart, K.
 Canlapan, D. See Juillard, G.
 Cannata, G. See Gebbia, V.
 Carencio, J. See Caudry, M.
 Carlier, D. See Adenis, A.
 Carpi, A.
 —Sagripanti, A.; Poddighe, R.; Gherarducci, G.; Nicolini, A.: Cancer incidence and mortality in patients with heart disease: Effect of oral anticoagulant therapy, 15
 Carrión, J. R.
 —García Arroyo, F. R.; Salinas, P.: Infusional chemotherapy (EPOCH) in patients with refractory or relapsed lymphoma, 44
 Carroll, R. See Reddy, S. P.
 Carson, L. F. See Asbury, R.
 Casselman, J. See Vandenbroucke, F.
 Cassileth, P. See Friedenberg, W. R.
 Caudry, M.
 —Bonnell, C.; Floquet, A.; Marsault, C.; Quélin, P.; Pujol, J.; Maton, O.; Dujols, J.-P.; Caudry, Y.; Skawinski, P.; Carencio, J.; Mokhtari, F.; Célérier, D.; Quinton, A.; Demaille, H.; Maire, J.-P.: A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma, 118
 Caudry, Y. See Caudry, M.
 Cavanna, L. See Federico, M.
 Célérier, D. See Caudry, M.
 Cellerino, R. See Graziano, F.
 Chaitchik, S. See Ron, I. G.
 Charyulu, K. N. See Broder, L. E.
 Chatikhine, V. A. See Francois, A.
 Chayama, K. See Ikeda, K.
 Chen, S.-C. See Keung, Y.-K.
 Chevallier, B. See Atlan, D.; Francois, A.
 Chevrier, A. See Francois, A.
 Cifarelli, R. A. See Golucci, G.
 Clark, J. L.
 —Küçük, Ö.; Neuberger, D. S.; Benson, A. B., III; Taylor, S. G., IV; Pandya, K. J.; Mansour, E. G.; Douglass, H. O., Jr.; Haller, D. G.: Phase II trial of etoposide, doxorubicin, and cisplatin combination in advanced measurable gastric cancer, 318
 Class, R.
 —Book reviews, 90
 Clendeninn, N. J. See Feun, L. G.
 Clerico, M. See Dogliotti, L.
 Cobb, P. See Krywicki, R.
 Coen, V.
 —Van Lancker, M.; De Neve, W.; Storme, G.: Prognostic factors in locoregional non-small cell lung cancer treated with radiotherapy, 111
 Comella, G. See Di Leo, A.
 Conroy, J. F. See Atree, S. V.
 Costa, M. A. See Velasco, E.
 Court, W. See Forman, J. D.
 Crawford, E. D. See Marshall, M. E.
 Crilley, P. A. See Atree, S. V.
 Crommelin, M. A. See Martijn, H.
 Cuevas, M. A. See Vallejo, C. T.
 Dahrouge, S. See Evans, W. K.; Steward, D. J.
 D'Angelo, L. See Arcangeli, G.
 D'Aprile, M. See Arcangeli, G.; Di Leo, A.
 Darloy, F. See Adenis, A.
 De Coene, N. See Van Lancker, M.
 De Neve, W. See Coen, V.
 de Neve, W. See Martijn, H.
 de Souza, P. L.
 —Friedlander, M. L.: Humoral hypercalcemia associated with adenocarcinoma of the rectum: A case report and review of the literature, 126
 Delanian, S. See Maulard, C.
 Delgado, F. M. See Bruno, S.
 Delgado, G. See Bruno, S.
 Delpech, B. See Francois, A.
 Demaille, A. See Adenis, A.
 Demeaux, H. See Caudry, M.
 Derluyn, J. See Vandenbroucke, F.
 Devi, S. See Forman, J. D.
 Di Gregorio, C. See Gebbia, V.
 Di Lallo, A. See Di Leo, A.
 Di Leo, A.
 —Bajetta, E.; Buzzoni, R.; Bochicchio, A. M.; Nolè, F.; Biganzoli, L.; D'Aprile, M.; Veltri, E.; Comella, G.; Aitini, E.; Di Lallo, A.; Santini, M.; Luccarelli, S.; Bian, A. R.: Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer, 239
 Di Renzo, N. See Federico, M.
 Dimitriadis, M. See Pectasides, D.
 Dion, J. E. See Larner, J. M.
 Djuric, L. See Jeremic, B.
 Dogliotti, L.
 —Bertetto, O.; Berruti, A.; Clerico, M.; Fanchini, L.; Sicora, W.; Faggiuolo, R.: Combination chemotherapy with carboplatin and methotrexate in the treatment of advanced urothelial carcinoma: A Phase II study, 78
 Donnelly, E. J. See Broder, L. E.
 Douglass, H. O., Jr. See Clark, J. L.
 Dujols, J.-P. See Caudry, M.
 Eijkenboom, W. M. H. See van Mierlo, I. J.
 Einstein, A. B. See Marshall, M. E.
 Eisenberger, M. See Marshall, M. E.
 Endoh, M. See Ogoshi, K.
 Ernstoff, M. S. See Agarwala, S. S.
 Espinoza-Jacobs, M. C.
 —Suntharalingam, M.; Eisenberger, M.; Sinibaldi, V.; Salazar, O. M.: Combined carboplatin plus bleomycin and conventional radiotherapy for advanced carcinomas of the head and neck, 52
 Evans, W. K. See Stewart, D. J.
 —Radwi, A.; Tomiak, E.; Logan, D. M.; Martins, H.; Stewart, D. J.; Goss, G.; Maroun, J. A.; Dahrouge, S.: Oral etoposide and carboplatin: Effective therapy for elderly patients with small cell lung cancer, 149
 Faggiuolo, R. See Dogliotti, L.
 Falkson, G.
 —Lipsitz, S.; Borden, E.; Simson, I.; Haller, D.: Hepatocellular car-

- cinoma: An ECOG randomized Phase II study of beta-interferon and menagoril, 287
- Fanchini, L.** See Dogliotti, L.
- Federico, M.**
- Gobbi, P. G.; Moretti, G.; Avanzini, P.; Di Renzo, N.; Cavanna, L.; Ascari, E.; Silingardi, V.: Effects of thymostimulin with combination chemotherapy in patients with aggressive non-Hodgkins lymphoma, 8
- Ferlazzo, G.**
- Magno, C.; Lupo, G.; Rizzo, M.; Iemmo, R.; Semino, C.; Melioli, G.: A Phase I study of intravesical continuous perfusion of recombinant interleukin-2 in patients with superficial bladder cancer, 100
- Fernandez, O.** See Bruno, S.
- Fernández-Trigo, V.**
- Shamsa, F.; Vidal-Jové, J.; Kern, D. H.; Sugarbaker, P. H.: Prognostic implications chemoresistance-sensitivity assays for colorectal and appendiceal cancer, 454
- Feun, L. G.**
- Robinson, W. A.; Savaraj, N.; Gonzalez, R.; Liebmann, A.; Offenhauer, K.; Clendeninn, N. J.: Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma, 488
- Florentino, B.** See Iacobelli, S.
- Fleshman, J.** See Myerson, R. J.
- Floquet, A.** See Caudry, M.
- Flores, M. R.**
- Sridhar, K. S.; Thurer, R. J.; Saldana, M.; Raub, W. A., Jr.: Klimas, N. G.: Lung cancer in patients with human immunodeficiency virus infection, 59
- Forman, J. D.**
- Warmelink, C.; Devi, S.; Court, W.; Sharma, R.; Yudeluv, M.; Porter, A. T.; Maughan, R.: Alternating conformal neutron and photon irradiation for locally advanced adenocarcinoma of the prostate, 231
- Formenti, S. C.**
- Lucas, G.; Ibarra, J. A.; Langholz, B.; Syed, N. M.; Puthawala, A. A.; Neblett, D.; Gowdy, R. A.; Petrovich, Z.: Initial brachytherapy in the breast conservation approach to breast cancer, 331
- Francois, A.**
- Chatikhine, V. A.; Chevallier, B.; Ren, G. S.; Berry, M.; Chevier, A.; Delpech, B.: Neuroendocrine primary small cell carcinoma of the breast: Report of a case and review of the literature, 133
- Franks, C.** See Antoine, E. C.
- Friedenberg, W. R.**
- Miller, H. J.; Marx, J. J., Jr.; Schloesser, L. L.; Reding, D. J.; Massa, J. J.; Hocking, W. G.; Mercier, R. J.; Raich, P. C.; Cassileth, P. A.: The treatment of older adult patients with acute myeloid leukemia by triple infusion chemotherapy, 105
- Friedlander, M. L.** See de Souza, P. L.
- Fry, R.** See Myerson, R. J.
- Gaitan, L.** See Bruno, S.
- Gano, J. B.** See Kleinerman, E. S.
- García Arroyo, F. R.** See Carrón, J. R.
- Garland, D.** See Krywicki, R.
- Garufi, C.** See Iacobelli, S.
- Gastineau, D. A.** See Letendre, L.
- Gaubert, P.** See Bruno, S.
- Gebbia, N.** See Gebbia, V.
- Gebbia, V.**
- Testa, A.; Di Gregorio, C.; Ingria, F.; Valenza, R.; Cannata, G.; Moschella, F.; Restivo, G.; Gebbia, N.: Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck, 293
- Gertz, M. A.**
- Kalish, L. A.; Kyle, R. A.; Hahn, R. G.; Tormey, D. C.; Oken, M. M.: Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 refractory or relapsed multiple myeloma, 475
- Getty, L.** See Nemunaitis, J.
- Gherarducci, G.** See Carpi, A.
- Ghironzi, G. C.** See Antoine, E. C.
- Giotta, F.** See Golucci, G.
- Giovinazzo, G.** See Arcangeli, G.
- Girdler, N. M.**
- McGurk, M.; Aqual, S.; Prince, M.: The effect of epidermal growth factor mouthwash on cytotoxic-induced oral ulceration: A phase I clinical trial, 403
- Giuliani, F.** See Golucci, G.
- Gobbi, P. G.** See Federico, M.
- Golucci, G.**
- Giotta, F.; Maiello, E.; Cifarelli, R. A.; Leo, S.; Giuliani, F.; Pezzella, G.; Pedicini, A.; Valori, V.: Efficacy of the association of folinic acid and 5-fluorouracil alone versus folinic acid and 5-fluorouracil plus 4-epidoxorubicin in the treatment of advanced gastric carcinoma, 519
- Gonzalez, R.** See Feun, L. G.
- Goor, C.** See Van Lancker, M.
- Goss, G.** See Evans, W. K.
- Gowdy, R. A.** See Formenti, S. C.
- Gralla, R. J.** See Rivera, M. P.
- Gramazio, A.** See Graziano, F.
- Graziano, F.**
- Cellerino, R.; Menestrina, F.; Nicoli, N.; Gramazio, A.; Latini, L.; Piga, A.: Synchronous primary hepatic lymphoma and epidermoid lung carcinoma treated with chemotherapy and surgery, 194
- Green, J. P.** See Sutton, J. B.
- Green, M.** See Bitran, J. D.; Olver, I.
- Greven, K. M.** See Mumber, M. P.
- Groschen, S.** See Keung, Y.-K.
- Grujicic, D.** See Jeremic, B.
- Hadley, T.** See Joseph, G.
- Hahn, R. G.** See Gertz, M. A.
- Haller, D. G.** See Clark, J. L.
- Hamm, J.** See Joseph, G.
- Hartmann, L. C.** See Ingle, J. N.
- Heelan, R. T.** See Miller, V. A.
- Hegg, R.** See Bruno, S.
- Heltzel, M.** See Sutton, J. B.
- Hempling, R. E.**
- Piver, M. S.; Baker, T. R.: Impact of progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (Adriamycin), and dacarbazine (CVADIC) chemotherapy for stage I uterine sarcoma: A prospective trial, 282
- Hendler, F.** See Joseph, G.
- Herndon, J. E., II** See Bitran, J. D.
- Herrada, J.**
- Cabanillas, F. F.: Multicentric Castleman's disease, 180
- Hoagland, H. C.** See Letendre, L.
- Hocking, W. G.** See Friedenberg, W. R.
- Hollis, D. R.** See Bitran, J. D.
- Homesley, H. D.** See Malfetano, J. H.
- Hosokawa, M.** See Kawata, A.
- Housset, M.** See Maulard, C.
- Howell, S. B.** See McClay, E. F.
- Hsu, C.-Y.** See Lin, J.-C.
- Huberman, M.** See Stuart, K.
- Hussein, A.** See Mudar, R.
- Iacobelli, S.**
- Garufi, C.; Irtelli, L.; Martino, M. T.; Santobuono, F.; Vicario, G.; Tinari, N.; Fiorentino, B.; Innocenti, P.; Natoli, C.: A Phase I study of recombinant interferon- α administered as a seven-day

- continuous venous infusion at circadian-rhythm modulated rate in patients with cancer, 27
- Ibarra, J. A.** See Formenti, S. C.
- Ibrahim, N. K.**
- Buzdar, A. U.: Aromatase inhibitors: Current status, 407
- Iemmo, R.** See Ferlazzo, G.
- Ikeda, K.**
- Saitoh, S.; Koida, I.; Tsubota, A.; Arase, Y.; Chayama, K.; Kumada, H.: A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization, 204
- Inbar, M. J.** See Ron, I. G.
- Ingle, J. N.**
- Krook, J. E.; Mailliard, J. A.; Hartmann, L. C.; Wieand, H. S.: Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer, 498
- Ingrai, R.** See Gebbia, V.
- Innocenti, P.** See Iacobelli, S.
- Irtelli, L.** See Iacobelli, S.
- Iseminger, K. A.** See Broun, E. R.
- Isono, K.** See Ogoshi, K.
- Jaffe, N.** See Kleinerman, E. S.
- Jan, J.-S.** See Lin, J.-C.
- Jane, J. A.** See Larner, J. M.
- Jansen, P. P.** See van Mierlo, I. J.
- Jenkins, T.** See Krywicki, R.
- Jennings, L. W.** See Nemunaitis, J.
- Jensen, M. E.** See Larner, J. M.
- Jeremic, B.**
- Grujicic, D.; Antunovic, V.; Djuric, L.; Shibamoto, Y.: Accelerated hyperfractionated radiation therapy or malignant glioma: A phase II study, 449
- Johnston, D. A.** See Kleinerman, E. S.
- Jones, A. S.**
- The untreated patient with squamous carcinoma of the head and neck, 363
- Jones, D., III** See Moor, D. F., Jr.; Pazdur, R.
- Jose, B.** See Seither, R. B.
- Joseph, G.**
- Hamm, J.; Morris, K.; Seeger, J.; Blumenreich, M.; Hadley, T.; Hender, F.; Woodcock, T.: Phase II trial of 5-fluorouracil, folinic acid, and N₁N₁, N₁1-triethylenethiophosphoramide (thiotepa) in patients with advanced breast cancer, 385
- Juillard, G.**
- Padua, D.; Canlapan, D.; McBride, W.: Resistance to common viruses during intralymphatic injections of tumor cell vaccines: correlation with circulating cytokines, 226
- Kagan, A. R.** See Smith, D. E.
- Kalaycioglu, M. E.**
- Lichtin, A. E.; Andresen, S. W.; Tuason, L.; Bolwell, B. J.: High-dose busulfan and cyclophosphamide followed by autologous bone marrow transplantation and/or peripheral blood progenitor cell rescue for metastatic breast cancer, 491
- Kalish, L. A.** See Gertz, M. A.
- Karlsson, U. L.** See Seegenschmiedt, M. H.
- Karp, A. H.** See Sutton, J. B.
- Kawata, A.**
- Une, Y.; Hosokawa, M.; Wakizaka, Y.; Namieno, T.; Uchino, J.; Kobayashi, H.: Adjuvant chemimmunotherapy for hepatocellular carcinoma patients, 257
- Kennedy, B. J.**
- Torkelson, J.: Optimal number of chemotherapy courses in advanced nonseminomatous testicular carcinoma, 463
- Kern, D. H.** See Fernández-Trigo, V.
- Kesselring, G.** See Bruno, S.
- Ketelbey, W.** See Olver, I.
- Keung, Y.-K.**
- Watkins, K.; Chen, S.-C.; Groshen, S.; Levine, A. M.; Douer, D.: Increased incidence of central venous catheter-related infections in bone marrow transplant patients, 469
- Khan, M. A.** See Malik, I. A.
- Khan, W. A.** See Malik, I. A.
- Khayat, D.** See Antoine, E. C.
- Kim, S.** See McClay, E. F.
- Kirmani, S.** See McClay, E. F.
- Kleinerman, E. S.**
- Gano, J. B.; Johnston, D. A.; Benjamin, R. S.; Jaffe, N.: Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma, 93
- Klimas, N. G.** See Flores, M. R.
- Klocker, J.**
- Sabitzer, H.; Raunik, W.; Wieser, S.; Schumer, J.: Combined application of cisplatin, vindesine, hyaluronidase and radiation for treatment of advanced squamous cell carcinoma of the head and neck, 425
- Kobayashi, H.** See Kawata, A.
- Kodner, I.** See Myerson, R. J.
- Koida, I.** See Ikeda, K.
- Kondo, M.** See Nishida, K.
- Kris, M. G.** See Miller, V. A.; Rivera, M. P.
- Krook, J. E.** See Ingle, J. N.
- Krywicki, R.**
- Bowen, K.; Anderson, L.; Garland, D.; Cobb, P.; Jenkins, T.; O'Rourke, T.: Mixed-lineage acute myeloid leukemia associated with a suprasellar dysgerminoma, 83
- Küçük, Ö.** See Clark, J. L.
- Kumada, H.** See Ikeda, K.
- Kyle, R. A.** See Gertz, M. A.
- Lacava, J. A.** See Vallejo, C. T.
- Lacey, D.** See Myerson, R. J.
- Lad, T.** See Reddy, S. P.
- Lamote, J.** See Van Lancker, M.
- Landolt-Weber, U.** See Stey, C.
- Landucci, M.** See Pronzato, P.
- Langhi, M. J.** See Vallejo, C. T.
- Langholz, B.** See Formenti, S. C.
- Larner, J. M.**
- Phillips, C. D.; Dion, J. E.; Jensen, M. E.; Newman, S. A.; Jane, J. A.: A Phase 1-2 trial of superselective carboplatin, low-dose infusional 5-fluorouracil and concurrent radiation for high-grade gliomas, 1
- Latini, L.** See Graziano, F.
- Leo, S.** See Golucci, G.
- Leone, B. A.** See Vallejo, C. T.
- Letendre, L.**
- Noel, P.; Tefferi, A.; Solberg, L. A., Jr.; Gastineau, D. A.; Hoagland, H. C.: Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia, 382
- Levendag, P. C.** See van Mierlo, I. J.
- Levin, B.** See Pazdur, R.
- Levine, A. M.** See Keung, Y.-K.
- Levitt, M. L.** See Schiller, J. H.
- Lichtin, A. E.** See Kalaycioglu, M. E.
- Liebmann, A.** See Feun, L. G.
- Lin, J.-C.**
- Jan, J.-S.; Hsu, C.-Y.: Neoadjuvant chemotherapy for advanced nasopharyngeal carcinoma, 139
- Lindberg, R. D.** See Seither, R. B.
- Linke, K. A.** See Patel, S. R.
- Lippman, S. M.** See Moor, D. F., Jr.
- Logan, D. M.** See Evans, W. K.
- Loman, P. L.** See LoRusso, P. M.
- Look, K. Y.** See Manetta, A.

- Blessing, J. A.; Williams, L.; Morris, M.: A phase II trial of merbarone (NSC 336628) as salvage therapy for squamous cell carcinoma of the cervix, 441
- Muss, H. B.; Blessing, J. A.; Morris, M.: A Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma, 19
- Lopez, M.** See Myerson, R. J.
- LoRusso, P. M.**
- Lomen, P. L.; Redman, B. G.; Poplin, E.; Bander, J. J.; Valdivieso, M.: Phase I study of monoclonal antibody-ricin A chain immunoconjugate Xomazyme-791 in patients with metastatic colon cancer, 307
- Louie, D.** See Sutton, J. B.
- Lucas, G.** See Formenti, S. C.
- Luccarelli, S.** See Di Leo, A.
- Lupo, G.** See Ferlazzo, G.
- Lybeert, M. L. M.** See Martijn, H.
- MacDonald, J. S.** See Williamson, S. K.
- Machiavelli, M. R.** See Vallejo, C. T.
- Maddox, A.-M.** See Williamson, S. K.
- Magno, C.** See Ferlazzo, G.
- Maiello, E.** See Golucci, G.
- Maillard, J. A.** See Ingle, J. N.
- Maire, J.-P.** See Caudry, M.
- Malfetano, J. H.**
- Blessing, J. A.; Homesley, H. D.: A phase II trial of gallium nitrate (NSC #15200) in nonsquamous cell carcinoma of the cervix, 495
- Malik, I. A.**
- Khan, W. A.; Qazilbash, M.; Ata, E.; Butt, A.; Khan, M. A.: Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin, 170
- Manetta, A.**
- Blessing, J. A.; Look, K. Y.: A Phase II study of fazarabine in patients with advanced ovarian cancer, 156
- Blessing, J. A.; Mann, W. J.; Smith, D. M.: A phase II study of fazarabine (NSC 281272) in patients with advanced squamous cell carcinoma of the cervix, 439
- Mann, W. J.** See Manetta, A.
- Mansour, E. G.** See Clark, J. L.
- Marincek, B.** See Stey, C.
- Markham, M.** See Sklarin, N. T.
- Markowitz, A.** See Pazdur, R.
- Marks, J. E.** See Reddy, S. P.
- Marmioli, L.** See Ausili-Céfaro, G.
- Maroun, J. A.** See Evans, W. K.
- Marsault, C.** See Caudry, M.
- Marshall, M. E.**
- Wolf, M. K.; Crawford, E. D.; Weiss, G. R.; Ahmann, F.; Meyers, F. J.; Blumenstein, B.; Eisenberger, M.; Einstein, A. B.: Phase II trial of CHIP for the treatment of advanced, hormonally refractory carcinoma of the prostate, 400
- Martijn, H.**
- de Neve, W.; Lybeert, M. L. M.; Crommelin, M. A.; Ribot, J. G.: Adjuvant postoperative radiotherapy for adenocarcinoma of the rectum and rectosigmoid: a retrospective analysis of locoregional control, survival, and prognostic factors on 178 patients, 277
- Martinez, L.** See Bruno, S.
- Martino, M. T.** See Iacobelli, S.
- Martins, C. A.** See Velasco, E.
- Martins, H.** See Evans, W. K.
- Marx, J. J., Jr.** See Friedenberg, W. R.
- Maton, O.** See Caudry, M.
- Maughan, R.** See Forman, J. D.
- Maulard, C.**
- Housset, M.; Brunel, P.; Delanian, S.; Taurelle, R.; Baillet, F.: Use of perioperative or split-course interstitial brachytherapy techniques for salvage irradiation of isolated local recurrences after conservative management of breast cancer, 348
- Mazza, J. J.** See Friedenberg, W. R.
- McBride, W.** See Juillard, G.
- McClay, E. F.**
- Braly, P. D.; Kirmani, S.; Plaxe, S. C.; Kim, S.; McClay, M. E.; Wilgus, L.; Howell, S. B.: A Phase II trial of intraperitoneal high-dose carboplatin and etoposide with granulocyte macrophage-colony stimulating factor support in patients with ovarian carcinoma, 23
- McClay, M. E.** See McClay, E. F.
- McGurk, M.** See Girdler, N. M.
- Meeuwis, C. A.** See van Mierlo, I. J.
- Melioli, G.** See Ferlazzo, G.
- Menestrina, F.** See Graziano, F.
- Mercier, R. J.** See Friedenberg, W. R.
- Meric, M.** See Aydin, A.
- Meyer, J. L.** See Sutton, J. B.
- Meyer, W.** See Nemunaitis, J.
- Meyers, F. J.** See Marshall, M. E.
- Micaily, B.** See Atree, S. V.
- Micheli, A.** See Arcangeli, G.
- Mickiewicz, E.** See Bruno, S.
- Miller, H. J.** See Friedenberg, W. R.
- Miller, V. A.**
- Rigas, J. R.; Pisters, K. M. W.; Pfister, D. G.; Heelan, R. T.; Kris, M. G.: Ifosfamide plus high-dose cisplatin in patients with non-small cell lung cancer previously treated with chemotherapy, 303
- Mitomi, T.** See Ogoshi, K.
- Mokhtari, F.** See Caudry, M.
- Moore, D. F., Jr.**
- Pazdur, R.; Sugarman, S.; Jones, D., III; Lippman, S. M.; Bready, B.; Abbruzzese, J. L.: Pilot phase II trial of 13- cis-retinoic acid and interferon- α combination therapy for advanced pancreatic adenocarcinoma, 525
- Moretti, G.** See Federico, M.
- Morgan-Ihring, C.** See Schiller, J. H.
- Morris, K.** See Joseph, G.
- Morris, M.** See Look, K. Y.
- Moschella, F.** See Gebbia, V.
- Moutzourides, G.** See Pectasides, D.
- Mudad, R.**
- Hussein, A.; Peters, W. P.: Guillain-Barre syndrome following autologous bone marrow transplantation, 167
- Mularoni, E.** See Antoine, E. C.
- Mullane, M.** See Reddy, S. P.
- Mumber, M. P.**
- Greven, K. M.: Control of advanced chemodectomas of the head and neck with irradiation, 389
- Muss, H. B.** See Look, K. Y.
- Myerson, R. J.**
- Shapiro, S. J.; Lacey, D.; Lopez, M.; Birnbaum, E.; Fleshman, J.; Fry, R.; Kodner, I.: Carcinoma of the anal canal, 32
- Nag, S.**
- The evolving role of brachytherapy in breast cancer, 353
- Nakamoto, H.** See Nishida, K.
- Namieno, T.** See Kawata, A.
- Namura, K.** See Nishida, K.
- Nardone, L.** See Ausili-Céfaro, G.
- Natoli, C.** See Iacobelli, S.
- Neblett, D.** See Formenti, S. C.
- Nemunaitis, J.**
- Rosenfeld, C.; Getty, L.; Boegel, F.; Meyer, W.; Jennings, L. W.; Zeigler, Z.; Shaddock, R.: Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome: A Phase II trial, 189
- Neuberg, D. S.** See Clark, J. L.
- Newman, S. A.** See Larner, J. M.

- Nicoli, N. See Graziano, F.
 Nicolini, A. See Carpi, A.
 Nishida, K.
 —Takano, H.; Ohtsuki, T.; Yoneda, M.; Nakamoto, H.; Terasawa, Y.; Yamane, E.; Nishioka, B.; Namura, K.; Yoshikawa, T.; Kondo, M.: Flow cytometric analysis of nuclear DNA content in the endoscopic biopsy tissues of gastric cancer, 325
 Nishioka, B. See Nishida, K.
 Noel, P. See Letendre, L.
 Noguera, C. See Bruno, S.
 Nolè, F. See Di Leo, A.
 Nowak, P. J. C. M. See van Mierlo, I. J.
 Nucci, M. See Velasco, E.
- Offenhauser, K. See Feun, L. G.
 Ogoshi, K.
 —Satou, H.; Isono, K.; Mitomi, T.; Endoh, M.; Sugita, M.: Immunotherapy for esophageal cancer: A randomized trial in combination with radiotherapy and radiochemotherapy, 216
 Ohtsuki, T. See Nishida, K.
 Olver, I.
 —Green, M.; Peters, W.; Zimet, A.; Toner, G.; Bishop, J.; Ketelbey, W.; Rastogi, R.; Birkhofer, M.: A Phase II trial of zeniplatin in metastatic melanoma, 56
 O'Rourke, T. See Krywicki, R.
 Otero, J. See Bruno, S.
- Padua, D. See Juillard, G.
 Pandya, K. J. See Clark, J. L.
 Papadopoulos, N. E. See Patel, S. R.
 Paridaens, R. See Vandenbroucke, F.
 Paris, K. J. See Seither, R. B.
 Patel, S. R.
 —Burgess, M. A.; Papadopoulos, N. E.; Linke, K. A.; Benjamin, R. S.: Extraskelatal myxoid chondrosarcoma: Long-term experience with chemotherapy, 161
 —Plager, C.; Papadopoulos, N. E.; Benjamin, R. S.: Myxoid malignant fibrous histiocytoma: Experience with chemotherapy, 528
 Pazardur, R. See Moor, D. F., Jr.
 —Bready, B.; Ajani, J. A.; Abbruzzese, J. L.; Markowitz, A.; Sugarman, S.; Jones, D.; Levin, B.: Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma, 436
 Pectasides, D.
 —Moutzourides, G.; Dimitriadis, M.; Varthalitis, J.; Athanassiou, A.: Chemotherapy for Merkel cell carcinoma with carboplatin and etoposide, 418
 Peddada, A. V. See Smith, D. E.
 Pedicini, A. See Golucci, G.
 Pei, Y. See Warner, E.
 Perez, J. E. See Vallejo, C. T.
 Perry, M. See Bitran, J. D.
 Peters, W. See Olver, I.
 Peters, W. P. See Mudar, R.
 Petrovich, Z. See Formenti, S. C.
 Pezzella, G. See Golucci, G.
 Pfister, D. G. See Miller, V. A.
 Phillips, C. D. See Lerner, J. M.
 Piga, A. See Graziano, F.
 Pion, J. M. See Adenis, A.
 Pisters, K. M. W. See Miller, V. A.
 Piver, M. S. See Hempling, R. E.
 Plager, C. See Patel, S. R.
 Plaxe, S. C. See McClay, E. F.
 Poddighe, R. See Carpi, A.
 Popelier, G. See Vandenbroucke, F.
 Poplin, E. See LoRusso, P. M.
 Porter, A. T. See Forman, J. D.
- Posner, M. See Stuart, K.
 Prince, M. See Girdler, N. M.
 Pronzato, P.
 —Landucci, M.; Vaira, F.; Viganì, A.; Bertelli, G.: Carboplatin, methotrexate, and vinblastine in outpatients with advanced transitional cell carcinoma of the bladder, 223
 Puerto, V. L. See Bruno, S.
 Pujol, J. See Caudry, M.
 Puthawala, A. A. See Formenti, S. C.
- Qazilbash, M. See Malik, I. A.
 Quélin, P. See Caudry, M.
 Quinton, A. See Caudry, M.
- Rabinovich, M. G. See Vallejo, C. T.
 Radwi, A. See Evans, W. K.
 Raich, P. C. See Friedenberg, W. R.
 Rao, R. K. See Broder, L. E.
 Rastogi, R. See Olver, I.
 Raub, W. A., Jr. See Broder, L. E.; Flores, M. R.
 Raunik, W. See Klocker, J.
 Reddy, S. P.
 —Lad, T.; Mullane, M.; Rosen, F.; Carroll, R.; Marks, J. E.: Radiotherapy alone compared with radiotherapy and chemotherapy in patients with squamous cell carcinoma of the esophagus, 376
 Reding, D. J. See Friedenberg, W. R.
 Redman, B. G. See LoRusso, P. M.
 Ren, G. S. See Francois, A.
 Restivo, G. See Gebbia, V.
 Ribot, J. G. See Martijn, H.
 Rigas, J. R. See Miller, V. A.
 Rivera, M. P.
 —Kris, M. G.; Gralla, R. J.; White, D. A.: Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy, 245
 Rixe, O. See Antoine, E. C.
 Rizzo, M. See Ferlazzo, G.
 Robinson, W. A. See Feun, L. G.
 Rodriguez, R. See Vallejo, C. T.
 Roelstraete, A. See Van Lancker, M.
 Romero, A. D. See Vallejo, C. T.
 Romero Acuña, J. See Vallejo, C. T.
 Romero Acuña, L. A. See Vallejo, C. T.
 Ron, I. G.
 —Amir, G.; Inbar, M. J.; Chaichik, S.: Clear cell chondrosarcoma of rib following repetitive low-impact trauma, 87
 Rosen, F. See Reddy, S. P.
 Rosenfeld, C. See Nemunaitis, J.
- Sabitzer, H. See Klocker, J.
 Sacre, R. See Van Lancker, M.
 Sagripanti, A. See Carpi, A.
 Saitoh, S. See Ikeda, K.
 Saldana, M. See Flores, M. R.
 Saldana, M. J. See Broder, L. E.
 Salinas, P. See Carrón, J. R.
 Salvi, G. See Ausili-Céfarò, G.
 Sanadi, R. E. See Bhagchandani, L.
 Santini, M. See Di Leo, A.
 Santobuono, F. See Iacobelli, S.
 Satou, K. See Ogoshi, K.
 Sattar, S. See Bhagchandani, L.
 Sauter, C. See Stey, C.
 Savaraj, N. See Feun, L. G.
 Schellhammer, P. F.
 —Patient counseling regarding treatment of T1/2 (A/B) prostate cancer, 532

- Schiller, J. H.
—Morgan-Ihring, C.; Levitt, M. L.: Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer, 47
- Schloesser, L. L. See Friedenberg, W. R.
- Schumer, J. See Klocker, J.
- Seegenschmiedt, M. H.
—Karlsson, U. L.; Black, P.; Brady, L. W.: Thermoradiotherapy for brain tumors, 510
- Seeger, J. See Joseph, G.
- Seither, R. B.
—Jose, B.; Paris, K. J.; Lindberg, R. D.; Spanos, W. J.: Results of irradiation in patients with high-grade gliomas evaluated by magnetic resonance imaging, 297
- Selawry, O. S. See Broder, L. E.
- Semino, C. See Ferlazzo, G.
- Seydel, H. G.
—Book review, 91
- Shaddock, R. See Nemunaitis, J.
- Shamsa, F. See Fernández-Trigo, V.
- Shapiro, S. J. See Myerson, R. J.
- Sharma, R. See Forman, J. D.
- Sheng, R. G. See Atlan, D.
- Shetty, M. R.
—Letter to the editor, 543
- Shibamoto, Y. See Jeremic, B.
- Sicora, W. See Dogliotti, L.
- Silingardi, V. See Federico, M.
- Skawinski, P. See Caudry, M.
- Sklar, N. T.
—Markham, M.: Spontaneous recurrent tumor lysis syndrome in breast cancer, 71
- Skorecki, K. L. See Warner, E.
- Smith, D. E.
—Bielamowicz, S.; Kagan, A. R.; Anderson, P. J.; Peddada, A. V.: Cutaneous neuroendocrine (Merkel cell) carcinoma: A report of 35 cases, 199
- Smith, D. M. See Asbury, R.; Manetta, A.
- Solberg, L. A., Jr. See Letendre, L.
- Solidoro, A. See Bruno, S.
- Soltys, K. M. See Stewart, D. J.
- Soubrane, C. See Antoine, E. C.
- Spanos, W. J. See Seither, R. B.
- Spiridonidis, C. H. See Williamson, S. K.
- Sridhar, K. S. See Broder, L. E.; Flores, M. R.
- Stewart, D. J. See Evans, W. K.
—Belanger, R.; Benjamin, R. S.: Prolonged disease-free survival following surgical debulking and high-dose cisplatin/doxorubicin in a patient with bulky metastases from giant cell tumor refractory to "standard" chemotherapy, 144
—Dahrouge, S.; Soltys, K. M.; Evans, W. K.: A Phase II study of 5-fluorouracil plus high-dose folinic acid in the treatment of recurrent small cell lung cancer, 130
- Stey, C.
—Landolt-Weber, U.; Vetter, W.; Sauter, C.; Marincek, B.: Malignant peritoneal mesothelioma after thorotrast exposure, 313
- Storme, G. See Coen, V.; Van Lancker, M.
- Stuart, K.
—Posner, M.; Campbell, K.; Huberman, M.: Cisplatin and chronic oral etoposide as salvage therapy for advanced colorectal carcinoma, 300
- Sugarbaker, P. H. See Fernández-Trigo, V.
- Sugarman, S. See Moor, D. F., Jr.; Pazdur, R.
- Sugita, M. See Ogoshi, K.
- Sutton, J. B.
—Green, J. P.; Meyer, J. L.; Louie, D.; Heltzel, M.; Karp, A. H.: Nasopharyngeal carcinoma: A study examining Asian patients treated in the United States, 337
- Syed, N. M. See Formenti, S. C.
- Szumowski, J. See Agarwala, S. S.
- Takano, H. See Nishida, K.
- Tangen, C. M. See Williamson, S. K.
- Taurelle, R. See Maulard, C.
- Taylor, S. G., IV See Clark, J. L.
- Tefferi, A. See Letendre, L.
- Terasawa, Y. See Nishida, K.
- Tersigni, R. See Arcangeli, G.
- Testa, A. See Gebbia, V.
- Texeira, L. C. See Bruno, S.
- Thurer, R. J. See Flores, M. R.
- Tinari, N. See Iacobelli, S.
- Tobe, S. W. See Warner, E.
- Tomiak, E. See Evans, W. K.
- Toner, G. See Olver, I.
- Topuz, E. See Aydinler, A.
- Torkelson, J. See Kennedy, B. J.
- Tormey, D. C. See Gertz, M. A.
- Trachtenberg, J. See Warner, E.
- Tralins, A. H.
—Lactation after conservative breast surgery combined with radiation therapy, 40
- Tsubota, A. See Ikeda, K.
- Tuason, L. See Kalaycioglu, M. E.
- Uchino, J. See Kawata, A.
- Ueno, N. T.
—Zukiwski, A. A.: Combination recombinant interleukin-2, recombinant interferon- α , and 5-fluorouracil for treatment of metastatic renal cell carcinoma, 358
- Une, Y. See Kawata, A.
- Vaira, F. See Pronzato, P.
- Valdivieso, M. See LoRusso, P. M.
- Valenza, R. See Gebbia, V.
- Vallejo, C. T.
—Rabinovich, M. G.; Perez, J. E.; Rodriguez, R.; Machiavelli, M. R.; Leone, B. A.; Romero, A. D.; Lacava, J. A.; Cuevas, M. A.; Langhi, M. J.; Romero Acuña, L. A.; Romero Acuña, J.; Amato, S.; Barbieri, M. R.: High-dose cisplatin with dipyrindamole in advanced non-small cell lung cancer, 185
- Valori, V. See Golucci, G.
- van Assendelft, P. J. See van Mierlo, I. J.
- Van Belle, S. See Van Lancker, M.
- Van Lancker, M. See Coen, V.
—Goor, C.; Sacre, R.; Lamote, J.; Van Belle, S.; De Coene, N.; Roelstraete, A.; Storme, G.: Patterns of axillary lymph node metastasis in breast cancer, 267
- van Mierlo, I. J.
—Levendag, P. C.; Eijkenboom, W. M. H.; Jansen, P. P.; Meeuwis, C. A.; van Assendelft, P. J.; van Putten, W. L. J.; Nowak, P. J. C. M.: Radiation therapy for cancer of the piriform sinus, 502
- Van Poppel, H. See Vandenbroucke, F.
- van Putten, W. L. J. See van Mierlo, I. J. M.
- Vandenbroucke, F.
—Van Poppel, H.; Derluyn, J.; Popelier, G.; Casselman, J.; Billiet, I.; Vanuytsel, L.; Paridaens, R.; Baert, L.: Interim results on a randomized trial of mitomycin C in combination with orchidectomy for newly diagnosed metastatic prostate cancer, 263
- Vanuytsel, L. See Vandenbroucke, F.
- Varthalitis, J. See Pectasides, D.
- Velasco, E.
—Costa, M. A.; Martins, C. A.; Nucci, M.: Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients, 429

Veltri, E. See Arcangeli, G.; Di Leo, A.
 Vetter, W. See Stey, C.
 Vicario, G. See Iacobelli, S.
 Vidal-Jové, J. See Fernández-Trigo, V.
 Vigan, A. See Pronzato, P.
 Vuillemin, E. See Antoine, E. C.

Wakizaka, Y. See Kawata, A.
 Warmelink, C. See Forman, J. D.
 Warner, E.

—Tobe, S. W.; Andrusis, I. L.; Pei, Y.; Trachtenberg, J.; Skorecki, K. L.: Phase II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma, 251

Watkins, K. See Keung, Y.-K.
 Weil, M. See Antoine, E. C.
 Weiser, S. See Klockner, J.
 Weiss, G. R. See Marshall, M. E.
 White, D. A. See Rivera, M. P.
 Wicand, H. S. See Ingle, J. N.

Wilgus, L. See McClay, E. F.
 Williams, L. See Look, K. Y.
 Williamson, S. K.

—Tangen, C. M.; Maddox, A.-M.; Spiridonidis, C. H.; MacDonald, J. S.: Phase II evaluation of low-dose continuous 5-fluorouracil and weekly cisplatin in advanced adenocarcinoma of the stomach, 484

Wilson, J. W. See Agarwala, S. S.
 Wolf, M. K. See Marshall, M. E.
 Woodcock, T. See Joseph, G.

Yamane, E. See Nishida, K.
 Yoneda, M. See Nishida, K.
 Yoshikawa, T. See Nishida, K.
 Yudeluv, M. See Forman, J. D.

Zeigler, Z. See Nemunaitis, J.
 Zimet, A. See Olver, I.
 Zukowski, A. A. See Ueno, N. T.

UNITED STATES POSTAL SERVICE Statement of Ownership, Management, and Circulation (Required by 39 U.S.C. 3685)

1. Publication Title: **American Journal of Clinical Oncology: Cancer Clinical Trials**

2. Publication No.: **0 2 7 7 - 3 7 3 2**

3. Filing Date: **October 1, 1995**

4. Issue Frequency: **Monthly**

5. No. of Issues Published Annually: **6**

6. Annual Subscription Price: **\$216 US/ \$252 Foreign**

7. Complete Mailing Address of Known Office of Publication (Street, City, County, State, and ZIP+4, Not PO Box):
12107 Insurance Way, Hagerstown MD 21740

8. Complete Mailing Address of Headquarters or General Business Office of Publisher (Not Printer):
12107 Insurance Way, Hagerstown MD 21740

9. Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor (Do Not Leave Blank):
 Publisher: **Lippincott-Raven Publishers, 227 E. Washington Square, Philadelphia PA 19106**
 Editor: **Dr. Luther M. Brady, Dept. of Radiation Oncology and Nuclear Medicine, Hahnemann University, Broad and Vine Streets, R6 2000, Philadelphia PA 19102**
 Managing Editor: **Greg Fagan, Lippincott-Raven Publishers, 1185 Ave of the Americas, NY NY 10036**

10. Owner (If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of the total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address as well as that of each individual must be given. If the publication is published by a nonprofit organization, its name and address must be stated.) (Do Not Leave Blank.)

Full Name	Complete Mailing Address
Lippincott-Raven Publishers	227 E. Washington Square, Philadelphia PA 19106
Wolters Kluwer US	1185 Avenue of the Americas NY, NY 10036
Wolters Kluwer nv (owns 100% of stock)	Stadhouderskade 1 1054 FS Amsterdam, The Netherlands

11. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Securities. If none, check box ☒ None.

12. For completion by nonprofit organizations authorized to mail at special rates. The purpose, function, and nonprofit status of this organization and the exempt status for federal income tax purposes. (Check one)
☐ Has Not Changed During Preceding 12 Months
☐ Has Changed During Preceding 12 Months (If changed, publisher must submit explanation of change with this statement.) (See instructions on Reverse.)

PS Form 3526, October 1994

1. Title of Publication: **American Journal of Clinical Oncology**

2. Issue Frequency: **Monthly**

3. Filing Date: **October 1, 1995**

4. Issue Frequency: **Monthly**

5. No. of Issues Published Annually: **6**

6. Annual Subscription Price: **\$216 US/ \$252 Foreign**

7. Complete Mailing Address of Known Office of Publication (Street, City, County, State, and ZIP+4, Not PO Box):
12107 Insurance Way, Hagerstown MD 21740

8. Complete Mailing Address of Headquarters or General Business Office of Publisher (Not Printer):
12107 Insurance Way, Hagerstown MD 21740

9. Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor (Do Not Leave Blank):
 Publisher: **Lippincott-Raven Publishers, 227 E. Washington Square, Philadelphia PA 19106**
 Editor: **Dr. Luther M. Brady, Dept. of Radiation Oncology and Nuclear Medicine, Hahnemann University, Broad and Vine Streets, R6 2000, Philadelphia PA 19102**
 Managing Editor: **Greg Fagan, Lippincott-Raven Publishers, 1185 Ave of the Americas, NY NY 10036**

10. Owner (If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of the total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address as well as that of each individual must be given. If the publication is published by a nonprofit organization, its name and address must be stated.) (Do Not Leave Blank.)

Full Name	Complete Mailing Address
Lippincott-Raven Publishers	227 E. Washington Square, Philadelphia PA 19106
Wolters Kluwer US	1185 Avenue of the Americas NY, NY 10036
Wolters Kluwer nv (owns 100% of stock)	Stadhouderskade 1 1054 FS Amsterdam, The Netherlands

11. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Securities. If none, check box ☒ None.

12. For completion by nonprofit organizations authorized to mail at special rates. The purpose, function, and nonprofit status of this organization and the exempt status for federal income tax purposes. (Check one)
☐ Has Not Changed During Preceding 12 Months
☐ Has Changed During Preceding 12 Months (If changed, publisher must submit explanation of change with this statement.) (See instructions on Reverse.)

PS Form 3526, October 1994

SUBJECT INDEX

- Acral lesion, basal cell carcinoma and, 176
- Adriamycin, See also Doxorubicin
 - with interleukin-2 and lymphokine-activated killer cells, versus adriamycin alone, in hepatocellular cancer, 257
 - with vincristine
 - and cyclophosphamide and dacarbazine, in uterine sarcoma, 282
 - and dexamethasone, compared to VAD plus interferon, in multiple myeloma, 475
- AIDS, lung cancer and, 59
- Amikacin with penicillin V, ciprofloxacin, and carbenicillin or ceftazidime, in febrile neutropenia, 429
- Aminoglycoside therapy, in febrile neutropenia, 429
- Aminothiadiazone, in leiomyosarcoma of uterine corpus, 397
- Anal canal, cancer of, 32
- Aneuploidy, in gastric cancer, 325
- Anthracycline therapy, cardiac toxicity and, 444
- Anticoagulants, cancer incidence and mortality in patients treated with, 15
- Appendiceal cancer, chemoresistance-sensitivity assay for, 454
- Aromatase inhibitors, in breast cancer, 407
- Arterial embolization, transcatheter, in hepatoma, 204
- Astrocytoma
 - carboplatin, 5-fluorouracil, and radiation in, 1 thermoradiotherapy in, 510
- Basal cell carcinoma, presenting as finger mass, 176
- Biological therapy, in pancreatic adenocarcinoma, 525
- Biopsy, endoscopic, flow cytometric analysis of nuclear DNA content in gastric cancer and, 325
- Bladder cancer, interleukin-2 in, 100
- Bleomycin
 - with carboplatin and radiotherapy, in head and neck cancer, 52
 - in peritoneal mesothelioma after thorotrast exposure, 313
- Bone, giant cell tumor of, 144
- Bone marrow transplant
 - in breast cancer, 491
 - central venous catheter-related infections in, 469
 - Guillain-Barre syndrome after, 167
 - in leukemia, esophageal cancer after, 343
- Book review
 - Clinical Flow Cytometry: Principles and Application* (by Bauer, KD et al), 90
 - Handbook of Flow Cytometry Methods* (Darzynkiewicz Z et al, eds), 90
 - Lung Cancer Differentiation: Implications for Diagnosis and Treatment* (Bernal S and Hesketh P, eds), 90
- Brachytherapy, in breast cancer, 331, 348, 353
- Brain tumor, thermoradiotherapy in, 510
- Breast cancer
 - aromatase inhibitors in, 407
 - axillary lymph node metastasis in, 267
 - bone marrow transplantation in, Guillain-Barre syndrome after, 167
 - brachytherapy in, 331, 348, 353
 - busulfan, cyclophosphamide, and bone marrow transplant and/or peripheral blood progenitor cell rescue in, 491
 - inflammatory, tamoxifen in, 74
 - lactation after surgery and radiation in, 40
 - mesna with ifosfamide in, 498
 - small-cell, primary, neuroendocrine, 133
 - spontaneous tumor lysis syndrome and, 71
 - thiotepa, with 5-fluorouracil, and folinic acid in, 385
- Breast-feeding, after surgery and radiation in breast cancer, 40
- Busulfan, with cyclophosphamide, and bone marrow transplant and/or peripheral blood progenitor cell rescue, in breast cancer, 491
- Carbenicillin, with ciprofloxacin, and penicillin V with amikacin, in febrile neutropenia, 429
- Carboplatin
 - with bleomycin and radiotherapy, in head and neck cancer, 52
 - with etoposide
 - and granulocyte macrophage-colony stimulating factors, in ovarian cancer, 23
 - in leukemia, 382
 - in small cell lung cancer, elderly patient and, 149
 - with 5-fluorouracil and radiation, in glioma, 1
 - with methotrexate
 - in urothelial cancer, 78
 - and vinblastine, in bladder cancer, 223
 - and radiotherapy, in head and neck cancer, 273
- Cardiac toxicity, epirubicin and, 444
- Castleman's disease, multicentric, 180
- Catheter, infection related to, 469
- Ceftazidime, with ciprofloxacin, and penicillin V with amikacin, in febrile neutropenia, 429
- Cervical cancer
 - nonsquamous cell, 495
 - squamous cell, fazarabine in, 439
- Chemodectoma, of head and neck, radiotherapy in, 389
- Chemoresistance-sensitivity assay, for colorectal and appendiceal cancer, 454
- Chemotherapy
 - acute dyspnea related to, 245
 - acute myocardial infarction after, 444
 - in advanced nonseminomatous testicular cancer, 463
 - in anal canal carcinoma, 32
 - in basal cell finger carcinoma, 176
 - in bladder cancer, 100, 223
 - in breast cancer, 71, 74, 133, 385, 392, 491, 498
 - in cervical cancer, 439, 441
 - in colorectal cancer, 118, 158, 300
 - in esophageal cancer, 216
 - in extraskeletal myxoid chondrosarcoma, 161
 - in febrile neutropenia, 429
 - in gastric cancer, 318, 484, 519
 - in giant cell tumor of bone, 144
 - in head and neck cancer, 52, 273, 293, 425
 - in hepatic lymphoma and epidermoid lung cancer, 194
 - in hepatocellular cancer, 257
 - in hepatoma, 204
 - in high-grade gliomas, 1
 - immunotherapy and
 - in hepatocellular cancer, 257
 - in metastatic melanoma, 421
 - interferon after, in small-cell lung cancer, 67
 - in leiomyosarcoma of uterine corpus, 397
 - in leukemia, 83, 105, 382
 - myeloid, older patient and, 105

- lorazepam for toxicity of, 170
- in lung cancer
- epidermoid, hepatic lymphoma and, 194
 - with human immunodeficiency virus, 56
 - non-small cell, 185, 303
 - small cell, 67, 118, 149
- in lymphoma, 8, 44
- hepatic, epidermoid lung cancer and, 194
 - non-Hodgkin, 8
- in malignant melanoma, 56, 421, 488
- in Merkel cell carcinoma, 418
- in multiple myeloma, 475
- in myelodysplastic syndrome, 189
- in myeloid leukemia, 83, 105
- in myxoid chondrosarcoma, 161
- in myxoid malignant fibrous histiocytoma, 525
- in nasopharyngeal carcinoma, 139
- in non-Hodgkin lymphoma, 8
- in non-small cell cancer, 47
- in non-small cell lung cancer, 185, 303
- oral ulceration and, 403
- orchidectomy and, in prostate cancer, 263
- in osteosarcoma, 93
- in ovarian cancer, 19, 23, 156, 164
- in peritoneal mesothelioma after thorotrast exposure, 313
- in prostate cancer, 239, 263, 400
- radiotherapy and
- in rectal tumors, 369
 - in squamous cell carcinoma of head and neck, 425
 - in squamous cell esophageal cancer, 376
- in renal cell cancer, 211, 251, 358
- in small cell lung cancer, 67, 118, 149
- in squamous cell cervical cancer, 439, 441
- with thymostimulin, in non-Hodgkin lymphoma, 8
- toxicity of, 245, 382, 403, 444
- triple infusion, in older patients with acute myeloid leukemia, 105
- in urothelial carcinoma, 78
- in uterine cancer, 282, 397
- CHIP, in prostate cancer, 400
- Chondrosarcoma
- myxoid, extraskeletal, 161
 - of rib, after repetitive low-impact trauma, 87
- Chronotherapy, 27
- Ciprofloxacin
- with penicillin V with amikacin, and carbenicillin or ceftazidime, in febrile neutropenia, 429
 - with pentoxifylline, in myelodysplastic syndrome, 189
- Circadian-rhythm modulated rate continuous venous infusion, in interferon administered as, 27
- Cisplatin
- with cytarabine, in metastatic colorectal cancer, 158
 - with dipyrindamole, in non-small cell lung cancer, 185
 - with doxorubicin
 - and etoposide, in gastric cancer, 318
 - and surgical debulking, in giant cell tumor of bone, 144 - with etoposide
 - in colorectal cancer, 300
 - and doxorubicin, in gastric cancer, 318 - with 5-fluorouracil, in advanced gastric cancer, 484
 - with ifosfamide, in non-small cell lung cancer, 303
 - lorazepam for toxicity induced by, 170
 - with tamoxifen and immunotherapy, in metastatic melanoma, 421
 - with vindesine, hyaluronidase, and radiotherapy, in squamous cell carcinoma of head and neck, 425
 - with vinorelbine, in squamous cell carcinoma of head and neck, 293
- Colon cancer, monoclonal antibody in, 307
- Colorectal cancer
- chemoresistance-sensitivity assay for, 454
 - cisplatin
 - with cytarabine in, 158
 - with etoposide in, 300 - 5-fluorouracil with folinic acid, versus 5-fluorouracil with cyclophosphamide and mitomycin C in, 118
 - isotretinoin with interferon in, 436
- Computed tomography, in peritoneal mesothelioma after thorotrast exposure, 313
- Counseling, patient, prostate cancer and, 532
- Cutaneous neuroendocrine carcinoma, 199
- Cyclophosphamide
- with busulfan, and bone marrow transplant and/or peripheral blood progenitor cell rescue, in breast cancer, 491
 - with 5-fluorouracil and mitomycin C, versus 5-fluorouracil with folinic acid, in colorectal cancer, 118
 - with vincristine, adriamycin, and dacarbazine, in uterine sarcoma, 282
- Cyclosporin A, with vinblastine, in renal cell cancer, 251
- Cytarabine, with cisplatin, in metastatic colorectal cancer, 158
- Cytokines, viral resistance and, 226
- Dacarbazine, with cyclophosphamide, vincristine, and adriamycin, in uterine sarcoma, 282
- Dexamethasone, with vincristine, and adriamycin, compared to VAD plus interferon, in multiple myeloma, 475
- Dipyridamole, with cisplatin, in non-small cell lung cancer, 185
- DNA content, in endoscopic biopsy tissue of gastric cancer, 325
- Doxorubicin, See also Adriamycin
- with cisplatin
 - and etoposide, in gastric cancer, 318
 - and surgical debulking, in giant cell tumor of bone, 144 - in myxoid malignant fibrous histiocytoma, 525
- Dysgerminoma, suprasellar, myeloid leukemia and, 83
- Dyspnea, related to combined mitomycin plus vinca alkaloid chemotherapy, 245
- Edatrexate, in previously treated ovarian cancer, 164
- Eldery, myeloid leukemia in, 105
- Emesis, lorazepam and, 170
- Enterocolitis, after etoposide with carboplatin for acute leukemia, 382
- Epidermal growth factor mouthwash, in cytotoxic-induced oral ulceration, 403
- Epidermoid lung cancer, hepatic lymphoma and, 194
- Epidoxorubicin
- with combination chemotherapy, in non-Hodgkin lymphoma, 8
 - with 5-fluorouracil and folinic acid, versus folinic acid with 5-fluorouracil, in gastric cancer, 519
- Epirubicin
- with medroxyprogesterone, in prostate cancer, 239
 - in non-Hodgkin lymphoma, myocardial infarction after, 444
- EPOCH, in lymphoma, 44
- Erratum: A Randomized Clinical Trial in Bronchogenic Small-Cell Carcinoma Evaluating Alternating Maintenance Therapy of Vincristine, Adriamycin, Procarbazine, and Etoposide (VAPE) with Cyclophosphamide, CCNU, and Methotrexate (CCM) versus CCM Maintenance Alone in Complete Responders Following VAPE Induction and Late Intensification, 462
- Esophageal cancer
- after allogeneic bone marrow transplant for acute leukemia, 343
 - immunotherapy in, 216
 - radiotherapy alone versus radiotherapy and chemotherapy in, 376
- Estrogen, aromatase inhibitors and, 407

- Etoposide
 with carboplatin
 and granulocyte macrophage-colony stimulating factors, in ovarian cancer, 23
 in leukemia, 382
 in Merkel cell carcinoma, 418
 in small cell lung cancer, elderly patient and, 149
 with cisplatin
 in colorectal cancer, 300
 and doxorubicin, in gastric cancer, 318
- Fazarabine
 in ovarian cancer, 156
 in squamous cell cervical cancer, 439
- Finger, basal cell carcinoma of, 176
- Flow cytometry, in gastric cancer, 325
- 5-Fluorouracil
 with carboplatin and radiation, in glioma, 1
 chemoresistance-sensitivity assay for, 454
 with cisplatin, in advanced gastric cancer, 484
 with folinic acid
 versus 5-fluorouracil with cyclophosphamide and mitomycin C, in colorectal cancer, 118
 in small cell lung cancer, 130
 and thiotepa, in breast cancer, 385
 with hyperfractionated radiotherapy, in rectal tumors, 369
 with interleukin-2 and interferon, in renal cell cancer, 358
 with leucovorin, in epithelial ovarian cancer, 19
 plus 4-epidoxorubicin with folinic acid, versus folinic acid with 5-fluorouracil, in gastric cancer, 519
- Folinic acid, with 5-fluorouracil
 versus 5-fluorouracil with cyclophosphamide and mitomycin C, in colorectal cancer, 118
 versus folinic acid with 5-fluorouracil plus 4-epidoxorubicin, in gastric cancer, 519
 in small-cell lung cancer, 130
 and thiotepa, in breast cancer, 385
- Gallium nitrate, in nonsquamous cell cervical cancer, 495
- Gastric cancer
 doxorubicin, etoposide, and cisplatin in, 318
 flow cytometric analysis of nuclear DNA content in biopsy tissue of, 325
 5-fluorouracil
 with cisplatin in, 484
 with epidoxorubicin and folinic acid, versus folinic acid with 5-fluorouracil, 519
- Giant cell tumor of bone, 144
- Glioma
 radiotherapy in, 449
 thermoradiotherapy in, 510
- Glomus tumor, of head and neck, radiotherapy in, 389
- Granulocyte macrophage-colony stimulating factors, with etoposide, and carboplatin, in ovarian cancer, 23
- Guillain-Barre syndrome, after autologous bone marrow transplantation, 167
- Head and neck cancer
 radiotherapy in
 carboplatin and, 273
 with bleomycin, 52
 piriform sinus and, 498
 squamous cell
 cisplatin
 with vindesine, hyaluronidase, and radiotherapy in, 425
 with vinorelbine in, 293
 untreated, 363
- Heart disease, cancer incidence and mortality in patients with, 15
- Hepatic lymphoma, epidermoid lung cancer and, 194
- Hepatocellular cancer
 adjuvant chemioimmunotherapy in, 257
 beta-interferon and menagoril in, 287
- Hepatoma, tegafur and uracil in, 204
- Histiocytoma, fibrous, malignant, myxoid, chemotherapy in, 525
- Hodgkin disease, infusional chemotherapy in, 44
- Hormonal therapy, aromatase inhibitors in, 407
- Hormone receptors, in metastatic inflammatory breast cancer, 74
- Human immunodeficiency virus, lung cancer and, 59
- Hyaluronidase, with cisplatin, vindesine, and radiotherapy, in squamous cell carcinoma of head and neck, 425
- Hypercalcemia, humeral, rectal adenocarcinoma and, 126
- Hyperthermia, interstitial, in brain tumor, 510
- Ifosfamide
 with cisplatin, in non-small cell lung cancer, 303
 with mesna, in breast cancer, 498
- Immunoconjugate, in colon cancer, 307
- Immunotherapy
 in bladder cancer, 100
 and chemotherapy, in metastatic melanoma, 421
 in esophageal cancer, 216
 in hepatocellular cancer, 257, 287
 with interferon, 27
 intralymphatic, resistance to common viruses during, 226
- Infection, catheter-related, bone marrow transplant and, 469
- Infusional therapy, in lymphoma, 44
- Interferon
 following combination chemotherapy, in small-cell lung cancer, 67
 with interleukin-2 and 5-fluorouracil, in renal cell cancer, 358
 with isotretinoin, in metastatic colorectal cancer, 436
 with menagoril, in hepatocellular cancer, 287
 with retinoic acid, in pancreatic adenocarcinoma, 525
 as seven-day continuous venous infusion at circadian-rhythm modulated rate, 27
- Interleukin-2
 with adriamycin and lymphokine-activated killer cells, versus adriamycin alone, in hepatocellular cancer, 257
 in bladder cancer, 100
 with interferon and 5-fluorouracil, in renal cell cancer, 358
 with tumor necrosis factor, in non-small cell lung cancer, 47
- Interperitoneal therapy, in ovarian cancer, 23
- Iodine-125, in breast cancer, 353
- Iridium-192, in breast cancer, 353
- Isotretinoin, with interferon, in metastatic colorectal cancer, 436
- Lactation, after breast surgery, and radiation therapy, 40
- Leiomyosarcoma, of uterine corpus, aminothiadiazole in, 397
- Leucovorin, with 5-fluorouracil, in epithelial ovarian cancer, 19
- Leukemia
 bone marrow transplant in, esophageal cancer after, 343
 carboplatin and etoposide in, 382
 myeloid
 in elderly, 105
 suprasellar dysgerminoma and, 83
- Leukopenia, methotrexate with carboplatin and, 78
- Liposome therapy, in osteosarcoma, 93
- Lorazepam, for cisplatin-induced toxicity, 170
- Lung cancer
 epidermoid, hepatic lymphoma and, 194
 human immunodeficiency virus and, 59
 non-small cell
 dipyridamole with cisplatin in, 185
 ifosfamide with cisplatin in, 303

- interleukin-2 and tumor necrosis factor in, 47
radiotherapy in, prognostic factors and, 111
- small-cell
carboplatin and etoposide in, elderly patient and, 149
5-fluorouracil and folinic acid in, 130
interferon after combination chemotherapy in, 67
- Lymph node metastases, in breast cancer, 267
- Lymphokine-activated killer cells, with adriamycin and interleukin-2, versus adriamycin alone, in hepatocellular cancer, 257
- Lymphoma
hepatic, epidermoid lung cancer and, 194
infusional chemotherapy in, 44
non-Hodgkin, acute myocardial infarction after epirubicin in, 444
- Magnetic resonance imaging, in high-grade glioma treated with radiotherapy, 297
- Massage, prostate bed, after radical prostatectomy, 481
- Medroxyprogesterone, with epirubicin, in prostate cancer, 239
- Melanoma, malignant
metastatic, zeniplatin in, 56
piritexim and DTIC in, 488
- Menagoril, and interferon, in hepatocellular cancer, 287
- Merbarone, in squamous cell cervical cancer, 441
- Merkel cell carcinoma, 199
carboplatin and etoposide in, 418
- Mesna, with ifosfamide, in breast cancer, 498
- Mesothelioma, peritoneal, thorotrast exposure and, 313
- Methotrexate, with carboplatin
in urothelial cancer, 78
and vinblastine, in bladder cancer, 223
- Metoclopramide, for cisplatin-induced toxicity, 170
- Mitomycin
chemoresistance-sensitivity assay for, 454
with cyclophosphamide and 5-fluorouracil, versus 5-fluorouracil with folinic acid, in colorectal cancer, 118
with orthidectomy, in prostate cancer, 263
with vinca alkaloid chemotherapy, acute dyspnea related to, 245
- Monoclonal antibody, in colon cancer, 307
- Multiple myeloma, vincristine, adriamycin, and dexamethasone, compared to VAD plus interferon in, 475
- Mucramyl tripeptide phosphatidylethanolamine, in osteosarcoma, 93
- Myelodysplastic syndrome, pentoxifylline with ciprofloxacin in, 189
- Myeloid leukemia
in elderly, 105
suprasellar dysgerminoma and, 83
- Myocardial infarction, after epirubicin for non-Hodgkin lymphoma, 444
- Myxoid chondrosarcoma, extraskelatal, 161
- Myxoid malignant fibrous histiocytoma, chemotherapy in, 525
- Nasopharyngeal cancer
neoadjuvant chemotherapy in, 139
radiotherapy in, 337
- Navelbine See Vinorelbine
- Nephrotoxicity, of ondansetron, 56
- Neuroendocrine carcinoma, cutaneous, 199
- Neuropeptides, neuroendocrine primary small cell breast cancer and, 133
- Neutropenia, febrile, ciprofloxacin, and penicillin V with amikacin, and carbenicillin or ceftazidime in, 429
- Non-Hodgkin lymphoma
epirubicin in, myocardial infarction after, 444
thymostimulin and combination chemotherapy in, 8
- Non-small cell lung cancer
dipyridamole and cisplatin in, 185
ifosfamide and cisplatin in, 303
- interleukin-2 and tumor necrosis factor in, 47
radiotherapy in, prognostic factors and, 111
- Nonsquamous cell carcinoma, cervical, 495
- Oat cell carcinoma, neuroendocrine primary small cell breast cancer and, 133
- Ondansetron, nephrotoxicity of, 56
- Orthidectomy, and mitomycin, in prostate cancer, 263
- Osteosarcoma, liposome therapy in, 93
- Ovarian cancer
carboplatin, etoposide, and granulocyte macrophage-colony stimulating factors in, 23
edatrexate in, 164
fazarabine in, 156
leucovorin and 5-fluorouracil in, 19
- Pancreatic adenocarcinoma, interferon and retinoic acid in, 525
- Parathyroid hormone related peptide, humeral hypercalcemia associated with rectal adenocarcinoma and, 126
- Penicillin V with amikacin, and ciprofloxacin, with carbenicillin or ceftazidime, in febrile neutropenia, 429
- Pentoxifylline, with ciprofloxacin, in myelodysplastic syndrome, 189
- Peripheral blood progenitor cell rescue, in breast cancer, 491
- Piriform sinus cancer, radiotherapy in, 498
- Piritexim, with DTIC, in malignant melanoma, 488
- Prostate cancer
CHIP in, 400
conformal neutron and photon radiotherapy in, 231
mitomycin C, and orchidectomy in, 263
patient counseling in, 532
prostate bed massage after radical prostatectomy and, 475
- Prostate specific antigen, after radical prostatectomy, prostate bed massage and, 475
- Prostatectomy, radical, prostate bed massage after, 475
- Quinidine, with vinblastine, in metastatic renal cell carcinoma, 211
- Radiosensitivity, lactation and, 40
- Radiotherapy
in advanced chemodectoma of head and neck, 389
in cancer of piriform sinus, 498
with carboplatin
and bleomycin, in head and neck cancer, 52
and 5-fluorouracil, in glioma, 1
in head and neck cancer, 273
chemotherapy and, in squamous cell carcinoma of head and neck, 425
in esophageal cancer, 216
with 5-fluorouracil, in rectal tumors, 369
in head and neck cancer, 52, 273, 389, 425, 498
hyperfractionated, in malignant glioma, 449
lactation after breast surgery and, 40
neutron and photon, in prostate adenocarcinoma, 231
in non-small cell lung cancer, prognostic factors in, 111
in oropharyngeal cancer, 337
in rectal cancer, 277
in squamous cell esophageal cancer, 376
- Rectal cancer
humeral hypercalcemia and, 126
isotretinoin and interferon in, 436
radiotherapy in, 277
- Rectal tumors, 5-fluorouracil and hyperfractionated radiotherapy in, 369
- Renal cell cancer
cyclosporin A with mitomycin in, 251
interleukin-2, 5-fluorouracil, and interferon in, 358
vinblastine and quinidine in, 211

- Retinoic acid, with interferon, in pancreatic adenocarcinoma, 525
- Retinoids
 - in colorectal cancer, 436
 - with interferon, in pancreatic adenocarcinoma, 525
- Rib, chondrosarcoma of, after repetitive low-impact trauma, 87
- Salvage therapy, infusional therapy as, 44
- Sarcoma, uterine, cyclophosphamide with vincristine, adriamycin, and dacarbazine in, 282
- Skin cancer, basal cell carcinoma and, 176
- Small-cell cancer
 - breast, primary, neuroendocrine, 133
 - bronchogenic (erratum), 462
 - lung
 - carboplatin and etoposide in, elderly patient and, 149
 - 5-fluorouracil and folinic acid in, 130
 - interferon after combination chemotherapy in, 67
- Squamous cell carcinoma
 - cervical
 - fazarabine in, 439
 - merbarone in, 441
 - esophageal, radiotherapy alone versus radiotherapy and chemotherapy in, 376
 - of head and neck, untreated, 363
- Suprasellar dysgerminoma, myeloid leukemia and, 83
- Tamoxifen
 - with cisplatin and immunotherapy, in metastatic melanoma, 421
 - in inflammatory breast cancer, 74
- Tegafur, with uracil, in hepatoma, 204
- Testicular cancer, optimal number of chemotherapy courses in, 463
- Thermoradiotherapy, in brain tumor, 510
- Thiotepa, with 5-fluorouracil, and folinic acid, in breast cancer, 385
- Thorotrast malignancy, peritoneal mesothelioma as, 313
- Thrombocytopenia, methotrexate with carboplatin and, 78
- Thymic hormones, with combination chemotherapy, in non-Hodgkin lymphoma, 8
- Thymostimulin, with combination chemotherapy, in non-Hodgkin lymphoma, 8
- Trauma, repetitive, chondrosarcoma of rib and, 87
- Tumor lysis syndrome, spontaneous, breast cancer and, 71
- Tumor necrosis factor, with interleukin-2, in non-small cell lung cancer, 47
- Ulceration, oral, epidermal growth factor mouthwash in, 403
- Uracil, with tegafur, in hepatoma, 204
- Urothelial cancer, methotrexate and carboplatin in, 78
- Uterine corpus, leiomyosarcoma of, aminothiadiazoole in, 397
- Uterus, sarcoma of, cyclophosphamide with vincristine, adriamycin, and dacarbazine in, 282
- Vinblastine
 - with carboplatin and methotrexate, in bladder cancer, 223
 - with cyclosporin A, in renal cell cancer, 251
 - with mitomycin, acute dyspnea related to, 245
 - with quinidine, in metastatic renal cell carcinoma, 211
- Vinca alkaloid chemotherapy, with mitomycin, acute dyspnea related to, 245
- Vincristine, with adriamycin
 - and cyclophosphamide, and dacarbazine, in uterine sarcoma, 282
 - and dexamethasone, compared to VAD plus interferon, in multiple myeloma, 475
- Vindesine
 - with cisplatin, hyaluronidase, and radiotherapy, in squamous cell carcinoma of head and neck, 425
 - with mitomycin, acute dyspnea related to, 245
- Vinorelbine
 - in breast cancer, 392
 - with cisplatin, in squamous cell carcinoma of head and neck, 293
 - with mitomycin, acute dyspnea related to, 245
- Virus, resistance to, during intralymphatic immunotherapy, 226
- Volar surface lesion, basal cell carcinoma and, 176
- Xomazyme 791, in colon cancer, 307
- Zeniplatin, in metastatic melanoma, 56